Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized

Executive Summary

Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.

You may also be interested in...



Pre-approval Promotion: Corporate Communications May Draw US FDA Scrutiny

Biopharma sponsors should start with information that needs to be disclosed to satisfy SEC rules and understand how a press release will be used to avoid running afoul of agency regulations, industry exec says; company contracts with investigators also should set limits on what they can say about an unapproved drug.

US FDA Reprimands Arog Pharmaceuticals For Promo Of Investigational AML Drug

Third enforcement letter of the year cites meeting exhibit and webpage that suggest crenolanib is safe and effective for an unapproved use.

US FDA Calls Foul On CSL Behring Hemophilia Drug Promo

Idelvion promotional materials misleadingly imply that patients can engage in high-risk activity without consequences; first letter from US biologics promo branch in three years.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119737

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel